16 studies found for:    Alzheimer's | Open Studies | United States, Utah
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Alzheimer's Disease
Intervention: Drug: AVP-786
2 Recruiting An Efficacy and Safety Study of LY3314814 in Early Alzheimer's Disease
Condition: Alzheimer´s Disease
Interventions: Drug: LY3314814;   Drug: Placebo
3 Recruiting A Study of LY3314814 in Participants With Mild Alzheimer's Disease Dementia
Condition: Alzheimer's Disease
Interventions: Drug: LY3314814;   Drug: Placebo
4 Recruiting Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Azeliragon;   Drug: Placebo
5 Recruiting Study Evaluating RVT-101 in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil Treatment: MINDSET Study
Condition: Alzheimer's Disease
Interventions: Drug: RVT-101;   Drug: Placebo
6 Recruiting Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Drug: AVP-786;   Drug: Placebo
7 Recruiting Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Drug: AVP-786;   Drug: Placebo
8 Recruiting 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037);   Drug: Placebo
9 Recruiting SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
Condition: Alzheimer's Disease
Interventions: Drug: SUVN-502;   Drug: Placebo
10 Recruiting CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Interventions: Drug: Crenezumab;   Drug: Placebo
11 Recruiting A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Conditions: Healthy;   Alzheimer's Disease;   Mild Cognitive Impairment
Interventions: Drug: LY2599666;   Drug: Solanezumab;   Drug: Placebo SC;   Drug: Placebo IV
12 Recruiting Implications for Management of PET Amyloid Classification Technology
Conditions: Mild Cognitive Impairment;   Dementia;   Alzheimer's Disease
Intervention: Drug: [18F]Flutemetamol
13 Recruiting A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
Condition: Alzheimer Disease
Interventions: Biological: LY3002813;   Drug: Placebo
14 Recruiting Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
Condition: Dementia
Intervention: Procedure: FDG-PET brain scan
15 Recruiting Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
Condition: Breast Cancer
Intervention: Drug: FDG-PET, [18F]Flutemetamol
16 Recruiting Cognitive Training and Practice Effects in MCI
Condition: Mild Cognitive Impairment
Intervention: Behavioral: computerized cognitive exercises

Indicates status has not been verified in more than two years